CTRI/2022/01/039274Other2 期
A Phase IIa, Adaptive, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study in Hospitalized Patients Infected with Severe and Critical SARS-CoV-2 to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001
试验速览
- 阶段
- 2 期
- 状态
- Other
- 发起方
- Medregen LLC
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Subject voluntarily agrees to participate in this study and is able to provide written informed consent or has a legal representative who can provide informed consent or is enrolled under International Conference on Harmonization (ICH) E6 (R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (where permitted according to local law and approved nationally and by the relevant IRB) prior to performing any of the Screening Visit procedures.
- •2 Males and females over 18 years of age, inclusive, at the time of signing the ICF.
- •3 Hospitalized, with COVID-19 symptoms of respiratory illness caused by SARS-CoV-2
- •infection (defined as Scale 5 â?? 7 on the WHO 8-point ordinal scale for clinical improvement.
- •4 Laboratory confirmation SARS-CoV-2 by real time polymerase chain reaction in the respiratory tract (NP swab, oropharyngeal swab, tracheal aspirate, BAL) lesser or equal to 14 days prior to randomization.
- •5 Radiologic findings compatible with diagnosis of SARS-CoV-2 pulmonary infection
- •6 Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period from the screening visit until the end of study visit. In the context of this study, an effective method is defined as those which result in low failure rate
- •(i.e. less than 1 percent per year) when used consistently and correctly such as:
- •-Combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)
- •-Progestogen only hormonal contraception associated with inhibition of Ovulation (oral, injectable, implantable)
- •-Intrauterine device (IUD)
- •-Intrauterine hormone releasing system
- •-Vasectomized partner
- •-Bilateral tubal occlusion
- •-True abstinence. When this is in line with the preferred and usual lifestyle of the subject.
- •Periodic abstinence, such as calendar, ovulation, symptothermal, post ovulation methods, and withdrawal are not acceptable methods of contraception.
- •7 Men must be willing to use a double barrier contraception from enrollment until at 5 months
- •after the last dose of study drug, if not abstinent.
排除标准
- •1 Participation in any other clinical trial of an experimental treatment for COVID-19 (remdesivir
- •use is permitted).
- •2 Significant pre existing organ dysfunction prior to randomization
- •-Lung: Receiving supplemental home oxygen therapy at baseline for pre-existing medical condition (other than COVID-19), as documented in medical record.
- •-Heart: Pre-existing congestive heart failure defined as an ejection fraction <20% as documented in the medical record. clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction (past 3 months), heart and coronary vessel surgery (past 3 months), significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic blood pressure >110 mm Hg.
- •-Renal: End-stage renal disease requiring renal replacement therapy or eGFR <30 mL/min
- •-Liver: Severe chronic liver disease defined as Child Pugh Class C
- •-Hematologic: Baseline platelet count <50,000/mm3
- •3 Concurrent treatment or prior use of drugs with actual or possible direct acting immunomodulatory activity against ARDS in COVID-19 is prohibited including JAK1/JAK2 inhibitor ruxolitinib, baricitinib and tofacitinib. However, IL-6 inhibitors such as tocilizumab, sarilumab are allowed if given >72 hours prior to first study dose. Corticosteroids are permitted throughout the study.
- •4 History of splenectomy or splenomegaly (spleen weighing >750 g)
- •5 Body mass index of >45 kg/m2 at screening
- •6 Underlying malignancy, or other condition, with estimated life expectancy of less than two months
- •7 Known family history of long QT syndrome (Torsades de Pointes) or currently taking medication that prolongs QT interval
- •8 Currently taking immunomodulating biologics (e.g., interferons, interleukin).
- •9 Extracorporeal membrane oxygenation (ECMO)
- •10 Use of two or more vasopressors
- •11 Female subjects who are pregnant or breastfeeding or planning to breastfeed at any time through 90 days after last dose of IP.
- •12 Received a live attenuated vaccine within 30 days prior to enrollment.
- •13 Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, human immunodeficiency virus (HIV) antibody or Active tuberculosis or a history of inadequately treated tuberculosis.
- •14 Ongoing immunosuppression: solid organ transplant recipients
- •15 Has used an investigational drug within 30 days prior to Screening.
- •16 History of hypersensitivity to MRG-001 (plerixafor [AMD3100, 24 mg/mL]) and tacrolimus [FK506, 0.5 mg/mL]) or any of the excipients or to medicinal products with similar chemical structure
- •17 Current treatment with an anti-viral medication for COVID-19 (e.g. hydroxychloroquine, lopinavir/ritonavir), other than remdesivir
- •18 Unable to understand the protocol requirements, instructions and study related restrictions, the nature, scope and possible consequences of the clinical study
- •19 Unlikely to comply with the protocol requirements, instructions and study related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study.
- •20 Previously been enrolled in this clinical study.
- •21 Vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly
研究者
相似试验
已完成
2 期
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with PD-L1 positive recurrent or metastatic HNSCCJPRN-jRCT2080225258600
已完成
2 期
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (study 209229)NL-OMON52820GlaxoSmithKline25
进行中（未招募）
1 期
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancerRecurrent/Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2019-002263-99-HUGlaxoSmithKline Research & Development Ltd600
进行中（未招募）
1 期
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancerRecurrent/Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2019-002263-99-GRGlaxoSmithKline Research & Development Ltd600
进行中（未招募）
1 期
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancerEUCTR2019-002263-99-NOGlaxoSmithKline Research & Development Ltd315